BERKELEY, Calif. and VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in the …
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving – an investor conference themed around investor education and advocacy begins next week, July 13th – 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1×1 meetings with qualified investors throughout the event. John Hope …
BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. Bria-OTS™, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to enter the clinic in 2021. BERKELEY, Calif. and VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: …
Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes BERKELEY, Calif. and VANCOUVER, British Columbia, June 10, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that …
BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that CEO Dr. William V. Williams will host a corporate and clinical update call on Wednesday, June 16, 2021 at …
BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the “Company” or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has closed its previously announced private placement of (i) 4,370,343 common shares at a purchase price of …
BERKELEY, Calif. and VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the “Company” or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has entered into definitive securities purchase agreements with accredited investors, which will result in gross proceeds to …
12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors ( 1) Top Responder: 21.4 months survival plus 100% resolution of ‘eye-bulging’ orbital tumor Compares to 7.2-9.8 months survival in historical comparison treatment trials ( 2) BERKELEY, Calif. and VANCOUVER, British Columbia, June 02, 2021 …
BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the …
BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences: • Benzinga …